{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T02:13:22Z","timestamp":1778292802218,"version":"3.51.4"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ctrv.2026.103127","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:49:19Z","timestamp":1775231359000},"page":"103127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comprehensive genomic profiling in solid tumours: Navigating promise, challenges, and pathways to clinical integration"],"prefix":"10.1016","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7840-558X","authenticated-orcid":false,"given":"Vittorio","family":"Studiale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ada","family":"Taravella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Landi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlotta","family":"Antoniotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Botticelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2026.103127_b0005","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41588-024-01785-9","article-title":"Analysis of 10,478 cancer genomes identifies candidate driver genes and opportunities for precision oncology","volume":"56","author":"Kinnersley","year":"2024","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2026.103127_b0010","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nature08987","article-title":"International network of cancer genome projects","volume":"464","author":"Hudson (Chairperson) TJ, Anderson W, Aretz A, Barker AD, Bell C, Bernab\u00e9 RR","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2026.103127_b0015","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1200\/JCO.2014.59.8433","article-title":"Basket trials and the evolution of clinical trial design in an era of genomic medicine","volume":"33","author":"Redig","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103127_b0020","doi-asserted-by":"crossref","unstructured":"Polley M-YC, Cheung YK. Early-Phase Platform Trials: A New Paradigm for Dose Finding and Treatment Screening in the Era of Precision Oncology. JCO Precis Oncol 2019;3:PO.19.00057. doi: 10.1200\/PO.19.00057.","DOI":"10.1200\/PO.19.00057"},{"key":"10.1016\/j.ctrv.2026.103127_b0025","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103127_b0030","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103127_b0035","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.annonc.2024.07.730","article-title":"The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development","volume":"35","author":"Westphalen","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103127_b0040","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","article-title":"Pilot study using molecular profiling of patients\u2019 tumors to find potential targets and select treatments for their refractory cancers","volume":"28","author":"Von Hoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103127_b0045","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Tourneau","year":"2015","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.ctrv.2026.103127_b0050","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41591-023-02379-4","article-title":"The NCI-MATCH trial: lessons for precision oncology","volume":"29","author":"O\u2019Dwyer","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103127_b0055","unstructured":"National Cancer Institute (NCI). Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study. clinicaltrials.gov; 2025."},{"key":"10.1016\/j.ctrv.2026.103127_b0060","unstructured":"National Cancer Institute (NCI). Molecular Analysis for Combination Therapy Choice (ComboMATCH). clinicaltrials.gov; 2025."},{"key":"10.1016\/j.ctrv.2026.103127_b0065","unstructured":"Health C for D and R. FoundationOne CDx (F1CDx) \u2013 P170019\/S048. FDA 2024."},{"key":"10.1016\/j.ctrv.2026.103127_b0070","unstructured":"Health C for D and R. TruSight Oncology Comprehensive - P230011. FDA 2024."},{"key":"10.1016\/j.ctrv.2026.103127_b0075","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1200\/JCO.2022.40.16_suppl.3130","article-title":"Increasing targeted therapy options for patients with relapsed cancer with broader somatic gene panel analysis from the primary tumor: The Profiler02 randomized phase II trial","volume":"40","author":"Tredan","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2026.103127_b0080","first-page":"1","article-title":"Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial","author":"Tr\u00e9dan","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103127_b0085","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.3390\/curroncol29030155","article-title":"Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer","volume":"29","author":"Gouton","year":"2022","journal-title":"Current Oncology"},{"key":"10.1016\/j.ctrv.2026.103127_b0090","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.annonc.2023.01.008","article-title":"Clinical utility of circulating tumor DNA sequencing with a large panel: aNational Center for Precision Medicine (PRISM) study","volume":"34","author":"Bayle","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103127_b0095","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41591-024-03244-8","article-title":"Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors","volume":"31","author":"Nakamura","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103127_b0100","doi-asserted-by":"crossref","first-page":"S1202","DOI":"10.1016\/j.annonc.2024.08.2245","article-title":"LBA7 The Rome trial from histology to target: The road to personalize targeted therapy and immunotherapy","volume":"35","author":"Botticelli","year":"2024","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.ctrv.2026.103127_b0105","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1038\/s41591-025-03918-x","article-title":"Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial","volume":"31","author":"Marchetti","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103127_b0110","article-title":"The Impact of Concordance Between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the Rome Trial","author":"Botticelli","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103127_b0115","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2023.03.041","article-title":"Do more targets allow more cancer treatments, or not?","volume":"187","author":"Marchetti","year":"2023","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.ctrv.2026.103127_b0120","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41571-025-01015-z","article-title":"Epidemiology, pathogenesis, biology and evolving management of MSI-H\/dMMR cancers","volume":"22","author":"Ambrosini","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103127_b0125","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2026.103127_b0130","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ctrv.2026.103127_b0135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High\/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103127_b0140","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial","volume":"17","author":"Muro","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103127_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability\/Mismatch Repair\u2013Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2026.103127_b0150","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMp1709968","article-title":"First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication","volume":"377","author":"Lemery","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103127_b0155","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.41165","article-title":"Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial","volume":"6","author":"Andr\u00e9","year":"2023","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.ctrv.2026.103127_b0160","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2026.103127_b0165","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103127_b0170","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103127_b0175","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103127_b0180","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1470-2045(18)30119-0","article-title":"Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1\/2 study","volume":"19","author":"Laetsch","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103127_b0185","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103127_b0190","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2023.41.16_suppl.3141","article-title":"Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer","volume":"41","author":"Hong","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2026.103127_b0195","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103127_b0200","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (TPX-0005) Is a Next-Generation ROS1\/TRK\/ALK Inhibitor That Potently Inhibits ROS1\/TRK\/ALK Solvent-","volume":"8","author":"Drilon","year":"2018","journal-title":"Front Mutations. Cancer Discov"},{"key":"10.1016\/j.ctrv.2026.103127_b0205","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 Fusion\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ctrv.2026.103127_b0210","doi-asserted-by":"crossref","unstructured":"Doebele RC, Lin JJ, Nagasaka M, Zhu VW, Gabrail NY, Bazhenova L, et al. TRIDENT-1: A global, multicenter, open-label Phase II study investigating the activity of repotrectinib in advanced solid tumors harboring ROS1 or NTRK1-3 rearrangements. JCO 2020;38:TPS9637\u2013TPS9637. doi: 10.1200\/JCO.2020.38.15_suppl.TPS9637.","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS9637"},{"key":"10.1016\/j.ctrv.2026.103127_b0215","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103127_b0220","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1200\/JCO.2012.44.1477","article-title":"RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non\u2013Small-Cell Lung Cancer","volume":"30","author":"Wang","year":"2012","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2026.103127_b0225","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","article-title":"RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients","volume":"23","author":"Kato","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.ctrv.2026.103127_b0230","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","article-title":"Selective RET kinase inhibition for patients with RET-altered cancers","volume":"29","author":"Subbiah","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103127_b0235","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103127_b0240","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1200\/JCO.2024.42.3_suppl.746","article-title":"Durable efficacy of selpercatinib in patients with RET fusion+ solid tumors, with a focus on GI tumors: LIBRETTO-001","volume":"42","author":"Subbiah","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2026.103127_b0245","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ctrv.2026.103127_b0250","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ctrv.2026.103127_b0255","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2026.103127_b0260","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2026.103127_b0265","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E\u2013Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study","author":"Tabernero","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ctrv.2026.103127_b0270","doi-asserted-by":"crossref","unstructured":"Elez E, Yoshino T, Shen L, Lonardi S, Cutsem EV, Eng C, et al. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer. New England Journal of Medicine n.d.;0. doi: 10.1056\/NEJMoa2501912.","DOI":"10.1056\/NEJMoa2501912"},{"key":"10.1016\/j.ctrv.2026.103127_b0275","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2026.103127_b0280","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103127_b0285","doi-asserted-by":"crossref","unstructured":"Bouffet E, Hansford J, Garr\u00e9 ML, Hara J, Plant-Fox A, Aerts I, et al. Primary analysis of a phase II trial of dabrafenib plus trametinib (dab + tram) in BRAF V600\u2013mutant pediatric low-grade glioma (pLGG). JCO 2022;40:LBA2002\u2013LBA2002. doi: 10.1200\/JCO.2022.40.17_suppl.LBA2002.","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA2002"},{"key":"10.1016\/j.ctrv.2026.103127_b0290","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1200\/JCO.22.01000","article-title":"Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma","volume":"41","author":"Bouffet","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103127_b0295","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies - a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103127_b0300","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ctrv.2026.103127_b0305","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606","volume":"33","author":"Lordick","year":"2022","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.ctrv.2026.103127_b0310","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1158\/1078-0432.CCR-18-2275","article-title":"Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer","volume":"25","author":"Meric-Bernstam","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103127_b0315","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103127_b0320","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ctrv.2026.103127_b0325","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.ctrv.2026.103127_b0330","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1200\/JCO.2023.41.16_suppl.3501","article-title":"Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing\/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study","volume":"41","author":"Raghav","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2026.103127_b0335","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2026.103127_b0340","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1200\/JCO-24-02026","article-title":"Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator\u2019s Choice in Chemorefractory KRAS G12C Colorectal Cancer","volume":"43","author":"Pietrantonio","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103127_b0345","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103127_b0350","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.ctrv.2026.103127_b0355","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in Non\u2013Small-Cell Lung Cancer Harboring a KRASG12C Mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ctrv.2026.103127_b0360","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C\u2013Mutated Advanced Pancreatic Cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ctrv.2026.103127_b0365","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103127_b0370","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103127_b0375","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/s41591-024-02934-7","article-title":"Pemigatinib in previously treated solid tumors with activating FGFR1\u2013FGFR3 alterations: phase 2 FIGHT-207 basket trial","volume":"30","author":"Rod\u00f3n","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103127_b0380","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.ctrv.2026.103127_b0385","unstructured":"Elevar Therapeutics. A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors. clinicaltrials.gov; 2025."},{"key":"10.1016\/j.ctrv.2026.103127_b0390","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2026.103127_b0395","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","article-title":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","volume":"25","author":"Li","year":"2024","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.ctrv.2026.103127_b0400","article-title":"The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)","volume":"10","author":"Verkerk","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103127_b0405","year":"2025","journal-title":"Study. clinicaltrials.gov"},{"key":"10.1016\/j.ctrv.2026.103127_b0410","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.annonc.2024.06.018","article-title":"ESMO Recommendations on clinical reporting of genomic test results for solid cancers","volume":"35","author":"van de Haar","year":"2024","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.ctrv.2026.103127_b0415","first-page":"1","article-title":"Real-world clinical utility of tumor whole-genome sequencing in solid cancers","author":"van Putten","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103127_b0420","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.ctrv.2026.103127_b0425","doi-asserted-by":"crossref","DOI":"10.1200\/PO.20.00372","article-title":"Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial","author":"Chen","year":"2021","journal-title":"JCO Precision Oncology"},{"key":"10.1016\/j.ctrv.2026.103127_b0430","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/annonc\/mdz080","article-title":"Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial","volume":"30","author":"Tr\u00e9dan","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103127_b0435","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41591-019-0424-4","article-title":"Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial","volume":"25","author":"Rodon","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103127_b0440","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103127_b0445","article-title":"patients in a Phase I setting","volume":"2025","author":"Belcaid","year":"2000","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.ctrv.2026.103127_b0450","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41698-025-00858-0","article-title":"A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer","volume":"9","author":"Volders","year":"2025","journal-title":"Npj Precis Onc"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T02:07:35Z","timestamp":1778292455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":90,"alternative-id":["S0305737226000411"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103127","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive genomic profiling in solid tumours: Navigating promise, challenges, and pathways to clinical integration","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103127","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103127"}}